ClinicalTrials.gg
RecruitingNCT07520162BIFANGUpdated Nov 12, 2026

A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab

A Phase 3 interventional study of Tezepelumab in Chronic Rhinosinusitis With Nasal Polyps, sponsored by AstraZeneca. Recruiting at 45 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Nov 12, 2026Site recruiting status changed11 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
230
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies in Nasal Polyps with a site in China — 17 open to participants now, 24 under way, 7 of them phase 3. Nasal Polyps · China.

Planned enrollment
10th of 43
230 · median 90
Started
2026
with 9 others
Phase 3
14 of 46
3 open now
Primary completion
2028-03
later than 19 of 23 live
Registered
42nd of 46
by date
Lead sponsor
4 of 46
AstraZeneca

Among the 46 studies in Nasal Polyps with a site in China, this one is the 10th largest by planned enrollment of the 43 interventional ones that give a count, is one of 10 that started in 2026, is one of 14 in phase 3, reaches primary completion later than 19 of the 23 other live ones, and was the 42nd registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

17 of the 46 studies in Nasal Polyps with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Nasal Polyps with a site in China, or all of them as a file.
02

Study summary

This is a multicentre, open-label, single-arm, Phase 3b study to assess nasal polyps score and symptoms in Chinese adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with tezepelumab.

Read the detailed description

This is a multicentre, open-label, single-arm, Phase 3b study to assess nasal polyps score and symptoms in Chinese adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with tezepelumab.

The study aims to enrol approximately 230 participants from approximately 30-50 sites in China. To ensure that participants' inflammatory endotypes of disease are represented appropriately in this study, restrictive inclusion criteria will be adopted to ensure that all participants have an eosinophilic endotype (defined by JESREC score of ≥ 11), with approximately 30% of participants having a JESREC score of ≥ 15. Eligible participants will receive tezepelumab at a fixed dose of 210 mg subcutaneously (SC) using an accessorised pre-filled syringe (APFS) every four weeks for up to 24 weeks.

03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps

Keywords

  • CRSwNP(Chronic Rhinosinusitis with Nasal Polyps)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age

    1. Participant must be 18 years of age or older, at the time of signing the .

  • Type of Participant and Disease Characteristics 2. Participants who are with physician-diagnosed CRSwNP for at least 12 months prior to Visit 1 who have all of the following:
  • Severity consistent with the need for surgery as defined by total NPS ≥ 4 (at least 2 for each nostril) at screening, as determined by the central reader
  • Mean NCS ≥ 2 in the 2 weeks prior to Visit 2
  • Ongoing documented NP symptoms for > 8 weeks prior to screening such as rhinorrhoea, reduction or loss of smell and/or poor quality/loss of sleep
  • SNOT-22 total score ≥ 30 as assessed at screening. 3. Any standard of care for treatment of CRSwNP, which must include treatment with intranasal , provided the participant is stable on that treatment for at least 30 days prior to Visit 1. Investigators should also ensure that participants are compliant and on a stable dose of the background INCS during study period.

    4. Either 1) documented treatment of NP exacerbation with SCS for at least 3 consecutive days or one IM depo-injectable dose (or /intolerance or intolerance to surgery) within the past 12 months prior to Visit 1 but not within the last 3 months prior to Visit 1 OR 2) any history of NP surgery (or contraindications/intolerance or intolerance to surgery).

    5. Participants with JESREC score of ≥ 11.

  • Weight 6. Body weight of ≥ 40 kg at Visit 1.
  • Sex and /Barrier Requirements 7. Male and/or female

Female participants:

  • Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Women of non- are defined as women who are either permanently sterilised (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are .
  • Women will be considered postmenopausal if they have been amenorrhoeic for 12 months prior to the planned start date of the first tezepelumab administration without an alternative medical cause.
  • The following age-specific requirements apply:

    • Women \< 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatment and FSH levels within the postmenopausal range.
    • Women > 50 years old would be considered postmenopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatment.
  • WOCBP must be willing to use one of the methods of contraception described hereafter, from the time of signing the ICF throughout the study and 16 weeks after last tezepelumab administration:

    • Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal
    • Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, implantable
    • Intrauterine device
    • Intrauterine hormone-releasing system
    • Bilateral tubal occlusion
    • Vasectomised partner (vasectomised partner is a highly effective birth control method provided that the partner is the sole sexual partner of the WOCBP participant and that the vasectomised partner has received medical assessment of the surgical success)
    • Sexual abstinence: it is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.
    • Cessation of contraception after this point should be discussed with a responsible physician.
  • Informed Consent 8. Provision of signed and dated written ICF prior to any mandatory study-specific procedures, sampling, and analyses.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

-Medical Conditions

  1. Participants with documented allergic fungal rhinosinusitis and/or central compartment atopic disease.
  2. Any pulmonary disease other than asthma (eg, active lung infection, bronchiectasis, pulmonary fibrosis, cystic fibrosis, primary ciliary dyskinesia, allergic bronchopulmonary mycosis, hypereosinophilic syndromes, etc) that could confound interpretation of clinical CRSwNP endpoints results.
  3. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:

    • Affect the safety of the participant throughout the study
    • Influence the findings of the study or the interpretation
    • Impede the participant's ability to complete the entire duration of study
  4. Sinus surgery within 6 months of screening visit OR any sinus surgery in the past which changed the lateral wall of the nose making NPS evaluation impossible.
  5. Participants with conditions or concomitant disease that makes them non-evaluable for the primary CRSwNP endpoints such as:

    • Antrochoanal polyps
    • Nasal septal deviation that occludes at least one nostril
    • Acute sinusitis, nasal infection, asthma exacerbation or upper respiratory infection at screening or in the two weeks before screening, or Churg-Strauss syndrome (also known as eosinophilic granulomatosis with polyangiitis), Young's syndrome or Kartagener's syndrome
  6. History of cancer:

    • Participants who have had basal cell carcinoma, localised squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to Visit 1
    • Participants who have had other are eligible provided that curative therapy was completed at least 5 years prior to Visit 1
  7. Uncontrolled epistaxis within 2 months of Visit 1.
  8. A helminth parasitic infection diagnosed within 6 months prior to Visit 1 that has not been treated with, or has failed to respond to, standard of care therapy.
  9. For participants with comorbid asthma: Current smokers or participants with a smoking history > 10 packs per year and participants using vaping products, including electronic cigarettes. Former smokers with a smoking history of \< 10 packs per year and users of vaping or e-cigarette products must have stopped for at least 6 months prior to Visit 1 to be eligible.
  10. History of chronic alcohol or drug abuse within 12 months prior to Visit 1.
  11. Tuberculosis requiring treatment within the 12 months prior to Visit 1. Particpiants who in the opinion of the investigator have evidence of active tuberculosis (TB), either treated or untreated, or latent TB without completion of an appropriate course of treatment or appropriate ongoing prophylactic treatment. Evaluation will be according to the local standard of care as determined by local guidelines and may consist of medical history and physical examinations, chest x-ray, sputum stain and/or culture, and/or TB test (eg, purified protein derivative or QuantiFeron test).
  12. Major surgery within 8 weeks prior to Visit 1 or planned NP surgery or planned surgical procedures requiring general anaesthesia or inpatient status for more than 1 day during the conduct of the study.
  13. History of known immunodeficiency disorder including a positive test at Visit 1, or the participant taking antiretroviral medications as determined by medical history and/or participant's verbal report.
  14. Infection requiring systemic antibiotics within 14 days prior to Visit 1. Note: Participants with respiratory infections requiring antibiotics within 14 days prior to Visit 1 may extend their screening period to allow recovery and return no sooner than 14 days after completion of therapy.

    -Prior/Concomitant Therapy

  15. Receipt of any marketed or biologic agent within 4 months or 5 half-lives (whichever is longer) prior to Visit 1 or receipt of any investigational non-biologic agent within 30 days or 5 half-lives (whichever is longer) prior to Visit 1.
  16. Treatment with systemic /immunomodulating drugs (eg, methotrexate, cyclosporine, etc.), except for SCS used in the treatment of asthma/asthma exacerbations, within the last 12 weeks or 5 half-lives (whichever is longer) prior to Visit 1.
  17. Receipt of immunoglobulin or blood products within 30 days prior to Visit 1.
  18. Receipt of 30 days prior to the date of Visit 1 and during the study including the follow-up period.
  19. Known history of sensitivity to any component of the tezepelumab formulation or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
  20. History of anaphylaxis or documented immune complex disease (Type III reactions) following any biologic therapy.
  21. Regular use of decongestants (topical or systemic) from Visit 1 onward is not allowed unless used for endoscopic procedure.
  22. Use of -eluting intranasal stents within 6 months prior to Visit 1 and during the study period.
  23. Recent aspirin desensitisation within 6 months of enrolment.

    -Prior/Concurrent Clinical Study Experience

  24. Concurrent enrolment in another clinical study involving a study intervention.

    -Diagnostic Assessments

  25. Any clinically meaningful abnormal finding in physical examination, haematology, or clinical chemistry at Visit 1 which, in the opinion of the investigator, may put the participant at risk because of his/her participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study.
  26. Evidence of active liver disease, including jaundice or , ALT, or ALP > 2 times at Visit 1.
  27. Positive surface antigen, or antibody serology at screening, or a positive medical history for hepatitis B or C. Participants with a history of hepatitis B vaccination without a history of hepatitis B are allowed to participate.

    -Other Exclusions

  28. Participants with JESREC score of \<11
  29. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site), or participants employed by or relatives of the relatives of the employees of the site or sponsor.
  30. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  31. For women only: Pregnant, breastfeeding, or lactating women. A serum β-HCG pregnancy test must be drawn for at the screening visit. If the results of the serum β-HCG cannot be obtained prior to dosing of the tezepelumab, a participant may be enrolled on the basis of a negative urine pregnancy test, though serum β-HCG must still be obtained. If either test is positive, the participant should be excluded. Since urine and serum tests may miss a pregnancy in the first days after conception, relevant menstrual history and sexual history, including methods of , should be considered. Any participant whose menstrual and/or sexual history suggests the possibility of early pregnancy should be excluded.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    Intervention Arm

    This is a multicentre, open-label, single-arm, Phase 3b study, all participants will be grouped into the same group for the study intervention.

    Drug: Tezepelumab

Interventions

  • At Visit 2 (Week 0), participants who meet the inclusion and exclusion criteria will receive tezepelumab treatment. All participants will receive tezepelumab 210 mg SC every four weeks (Q4W) from Week 0 (Visit 2), with the last dose administered at Week 20 (Visit 7). All tezepelumab administration will occur at the study site. Each participant who completes the study without discontinuing study intervention will receive a total of 6 doses of tezepelumab.

    Also known as: TEZSPIRE®

06

What researchers measure

Primary outcomes

  1. To describe changes from baseline in nasal polyp score (NPS)

    Change from baseline in total NPS evaluated by nasal endoscopy at Week 24 NPS: score 0-4 for each item, 4 indicates worse outcome

    Time frame: baseline-week24

  2. To describe changes from baseline in participant-reported nasal congestion as evaluated by nasal congestion score (NCS)

    Change from baseline in bi-weekly mean nasal congestion score (NCS) evaluated as part of the Nasal Polyposis Symptom Diary (NPSD) at Week 24. NCS: score 0-3, 3 indicates worse outcome

    Time frame: baseline-week24

Secondary outcomes

  1. To describe responder proportion in participant-reported nasal congestion as evaluated by the NCS following initiation of tezepelumab treatment

    Proportion of NCS responders (minimal clinically important difference \[MCID\] from baseline = -1.0) at each collected timepoint. NCS: score 0-3, 3indicates worse outcome

    Time frame: Daily for the 2 weeks prior to Week 0 through end of treatment visit (EOT; Week 24)

  2. To describe time to response and changes in participant-reported nasal congestion as evaluated by the NCS following initiation of tezepelumab treatment

    Description of time to first response for NCS. NCS: score 0-3, 3indicates worse outcome

    Time frame: Daily for the 2 weeks prior to Week 0 through end of treatment visit (EOT; Week 24)

  3. To describe changes in participant-reported nasal congestion as evaluated by the NCS following initiation of tezepelumab treatment

    Change from baseline in NCS at each collected timepoint in daily score. NCS: score 0-3, 3indicates worse outcome

    Time frame: Daily for the 2 weeks prior to Week 0 through end of treatment visit (EOT; Week 24)

  4. To describe responder proportion in NPS following initiation of tezepelumab treatment

    Proportion of participants with (i) ≥ 1 point reduction and (ii) ≥ 2 points reduction in NPS at Week 24. NPS: score 0-4 for each item, 4 indicates worse outcome

    Time frame: Baseline, Weeks 0, 4, 12, and 24

  5. To describe time to response in NPS following initiation of tezepelumab treatment

    Description of time to first response for NPS (≥ 1 point reduction) NPS: score 0-4, 4 indicates worse outcome

    Time frame: Baseline, Weeks 0, 4, 12, and 24

  6. To describe changes in NPS following initiation of tezepelumab treatment

    Change from baseline over time in NPS evaluated by nasal endoscopy through Week 24. NPS: score 0-4, 4 indicates worse outcome

    Time frame: Baseline, Weeks 0, 4, 12, and 24

  7. To describe numbers of CRSwNP exacerbation following initiation of tezepelumab treatment

    * Description of numbers of CRSwNP exacerbation during treatment period (Week 0 to 24) at Week 24 * Description of annualized CRSwNP exacerbation rate

    Time frame: Baseline, Weeks 0, 4, 12, and 24

  8. To describe responder proportion in sino-nasal symptoms as evaluated by sino-nasal outcome test, 22 item (SNOT-22) total score following initiation of tezepelumab treatment

    Proportion of SNOT-22 responder (MCID from baseline=-8.9) at each collected timepoint. SNOT-22: score 0-5 for each item, 5 means worse outcome

    Time frame: Baseline, Weeks 0, 4, 8, 12, 16, 20, and 24

  9. To describe time to first response in sino-nasal symptoms as evaluated by sino-nasal outcome test, 22 item (SNOT-22) total score following initiation of tezepelumab treatment

    Description of time to first response for SNOT-22. SNOT-22: score 0-5 for each item, 5 means worse outcome

    Time frame: Baseline, Weeks 0, 4, 8, 12, 16, 20, and 24

  10. To describe changes in sino-nasal symptoms as evaluated by sino-nasal outcome test, 22 item (SNOT-22) total score following initiation of tezepelumab treatment

    Change from baseline in SNOT-22 at each collected timepoint. SNOT-22: score 0-5 for each item, 5 means worse outcome

    Time frame: Baseline, Weeks 0, 4, 8, 12, 16, 20, and 24

  11. To describe changes in nasal blockage (NB) as evaluated by peak nasal inspiratory flow (PNIF)

    Change from baseline visit in NB measured by PNIF. Higher PNIF values indicate improved nasal airflow.

    Time frame: Weeks 0, 4, 12, and 24

  12. To describe responder proportion in nasal blockage (NB) as evaluated by peak nasal inspiratory flow (PNIF)

    Proportion of PNIF responder (MCID from baseline = 20 L/min)

    Time frame: Weeks 0, 4, 12, and 24

  13. To describe time to responder in nasal blockage (NB) as evaluated by peak nasal inspiratory flow (PNIF)

    Description of time to first response for PNIF

    Time frame: Weeks 0, 4, 12, and 24

  14. To describe responder proportion in sense of smell as evaluated as part of the NPSD

    * Change from baseline in bi-weekly mean loss of smell evaluated as part of the NPSD at Week 24 * Changes from baseline in loss of smell at all collected time points (daily)

    Time frame: Baseline-Week24

  15. To describe time to responder in sense of smell as evaluated as part of the NPSD.

    * Change from baseline in bi-weekly mean loss of smell evaluated as part of the NPSD at Week 24 * Changes from baseline in loss of smell at all collected time points (daily)

    Time frame: Baseline-Week24

  16. To describe changes in sense of smell as evaluated as part of the NPSD

    * Change from baseline in bi-weekly mean loss of smell evaluated as part of the NPSD at Week 24 * Changes from baseline in loss of smell at all collected time points (daily)

    Time frame: Baseline-Week24

  17. To describe responder proportion in sleep as evaluated by SNOT-22 sleep domain following initiation of tezepelumab treatment

    Proportion of SNOT-22 sleep domain responders (MCID from baseline = -2.9). SNOT-22: score 0-5 for each item, 5 means worse outcome

    Time frame: Baseline, Weeks 0, 4, 8, 12, 16, 20, and 24

  18. To describe time to responder in sleep as evaluated by SNOT-22 sleep domain following initiation of tezepelumab treatment

    Description of time to first response for SNOT-22 sleep domain . SNOT-22: score 0-5 for each item, 5 means worse outcome

    Time frame: Baseline, Weeks 0, 4, 8, 12, 16, 20, and 24

  19. To describe changes in sleep as evaluated by SNOT-22 sleep domain following initiation of tezepelumab treatment

    Changes from baseline in SNOT-22 sleep domain score。 SNOT-22: score 0-5 for each item, 5 means worse outcome

    Time frame: Baseline, Weeks 0, 4, 8, 12, 16, 20, and 24

  20. To describe responder proportion in overall symptoms as evaluated by NPSD total nasal symptom score (TSS) following initiation of tezepelumab

    Proportion of TSS responder (MCID from baseline = -4.0)

    Time frame: Daily for the 2 weeks prior to Week 0 and through EOT (Week 24)

  21. To describe time to responder in overall symptoms as evaluated by NPSD total nasal symptom score (TSS) following initiation of tezepelumab

    Description of time to first response for TSS

    Time frame: Daily for the 2 weeks prior to Week 0 and through EOT (Week 24)

  22. To describe changes in overall symptoms as evaluated by NPSD total nasal symptom score (TSS) following initiation of tezepelumab

    Changes from baseline in TSS in daily score

    Time frame: Daily for the 2 weeks prior to Week 0 and through EOT (Week 24)

  23. To describe the change on sinus opacification following initiation of tezepelumab.

    Change from baseline in Lund-Mackay score (LMK) evaluated by CT at Week 24 as determined by the central reader. Lund-Mackay score: 0-12 each item, 12 means worse outcome

    Time frame: Baseline, Week 24

  24. To describe the change in lung function with co-morbid asthma following initiation of tezepelumab.

    Change from baseline in pre-BD FEV1 at Week 24

    Time frame: Baseline, Week12, Week24

  25. To describe the change in ACQ-5 in participants with co-morbid asthma following initiation of tezepelumab.

    * Change from baseline in ACQ-5 at Week 24. * The ACQ-5 total score is the mean of the 5 responses. Mean scores of ≤ 0.75 indicate well-controlled asthma, scores between 0.75 and \< 1.5 indicate partly controlled asthma, and a score ≥ 1.5 indicates not well-controlled asthma. Individual changes of at least 0.5 are considered to be clinically meaningful.

    Time frame: Baseline and 24

  26. To describe the change in asthma exacerbation in participants with co-morbid asthma following initiation of tezepelumab.

    Description of numbers of asthma exacerbation in participants with comorbid asthma during treatment period (Week 0-24) at Week 24

    Time frame: week0-24

  27. To describe the change in asthma exacerbation in participants with co-morbid asthma following initiation of tezepelumab.

    Description of AAER in participants with comorbid asthma

    Time frame: week0-24

Other outcomes

  1. To evaluate the safety and tolerability of tezepelumab

    Adverse events (AEs), Serious adverse events(SAEs), Discontinuations of study intervention due to an AE(DAEs), AE of special interest(AESIs)

    Time frame: week0-24

  2. To evaluate the need for nasal polyp surgery up to Week 24

    Time to NP surgery decision up to Week 24

    Time frame: Baseline-Week24

  3. To evaluate the need for SCS use up to Week 24

    Description of SCS use up to Week 24

    Time frame: Baseline-Week24

  4. To evaluate the changes in key type 2 inflammatory mediators in the serum following initiation of tezepelumab

    Changes in concentration levels of inflammatory cytokines \[TT22.1\]\[AX22.2\]in serum from baseline to Week 24: IL-5, IL-13, EDN by ELISA, summarized by mean change

    Time frame: Baseline and the Week 24

  5. To evaluate changes in local tissue immune cell infiltration and systemic inflammatory markers in the serum following initiation of tezepelumab

    Changes in cell counts of granulocytes in nasal polyp tissue biopsy from baseline to Week 24 by HE staining: eosinophils and neutrophils

    Time frame: Baseline and the Week 24

  6. To evaluate changes in local tissue immune cell infiltration and systemic inflammatory markers in the serum following initiation of tezepelumab

    Changes in concentration levels of inflammatory cytokines in serum from baseline to Week 24: IL-33, TSLP, IL-25, amphiregulin, Eotaxin 1, Eotaxin 2, Eotaxin 3, CCL17, IL-17, IL-22, IFN-γ, IL-6, IL-8, Periostin, and GZMK\[QZ23.1\]\[AX23.2\],summarized by mean change.

    Time frame: Baseline and the Week 24

  7. To further elucidate the underlying mechanisms of tezepelumab treatment and to identify predictive biomarkers for treatment response.

    Changes in the percentage (%) of peripheral blood memory T cell and ILC2 populations by flow cytometry-based assessment

    Time frame: Baseline, Weeks 12 and 24

  8. To further elucidate the underlying mechanisms of tezepelumab treatment and to identify predictive biomarkers for treatment response.

    Changes in nasal microbiome composition by 16S rRNA sequencing from nasal swabs

    Time frame: Baseline and Week 24

  9. To further elucidate the underlying mechanisms of tezepelumab treatment and to identify predictive biomarkers for treatment response.

    Changes in the transcriptomic profile and gene expression levels by RNA sequencing from baseline to Week 24: IL-33, TSLP, IL-25, amphiregulin, CCL17, Periostin, GZMK, and neuropeptides

    Time frame: Baseline and Week 24

  10. To further elucidate the underlying mechanisms of tezepelumab treatment and to identify predictive biomarkers for treatment response.

    Changes in concentration levels of inflammatory cytokines in nasal secretion from baseline \[QZ25.1\]\[AX25.2\]to Week 24: IL-5, IL-13, IL-33, TSLP, IL-25, Amphiregulin, Eotaxin 1, Eotaxin 2, Eotaxin 3, CCL17, IL-17, IL-22, IFN-γ, IL-6, IL-8, Periostin, GZMK, EDN, and neuropeptides

    Time frame: Baseline and Week 24

07

Study locations

36 of 45 sites recruiting
  • Research Site
    Beijing, 100034, China
    Recruiting
  • Research Site
    Beijing, 100730, China
    Recruiting
  • Research Site
    Beijing, China
    Not yet recruiting
  • Research Site
    Bengbu, 233004, China
    Recruiting
  • Research Site
    Cangzhou, 061000, China
    Recruiting
  • Research Site
    Changchun, China
    Recruiting
  • Research Site
    Changsha, 410011, China
    Recruiting
  • Research Site
    Changsha, 410013, China
    Recruiting
  • Research Site
    Changsha, China
    Not yet recruiting
  • Research Site
    Chengdu, 610021, China
    Recruiting
  • Research Site
    Chengdu, 610041, China
    Recruiting
  • Research Site
    Chengdu, 610075, China
    Recruiting
  • Research Site
    Chengdu, 610078, China
    Recruiting
  • Research Site
    Chongqing, 400016, China
    Recruiting
  • Research Site
    Foshan, 528000, China
    Recruiting
  • Research Site
    Fuzhou, 350005, China
    Recruiting
  • Research Site
    Guangzhou, 510120, China
    Recruiting
  • Research Site
    Guangzhou, China
    Not yet recruiting
  • Research Site
    Guiyang, 550044, China
    Recruiting
  • Research Site
    Hangzhou, China
    Not yet recruiting
  • Research Site
    Hefei, China
    Not yet recruiting
  • Research Site
    Hohhot, China
    Not yet recruiting
  • Research Site
    Huaian, 223300, China
    Recruiting
  • Research Site
    Kunming, 650032, China
    Recruiting
  • Research Site
    Lanzhou, 730030, China
    Recruiting
  • Research Site
    Nanchang, 330006, China
    Recruiting
  • Research Site
    Nanchang, 330052, China
    Recruiting
  • Research Site
    Nanning, China
    Not yet recruiting
  • Research Site
    Ningbo, 315100, China
    Recruiting
  • Research Site
    Qingdao, 110016, China
    Recruiting
  • Research Site
    Shanghai, China
    Not yet recruiting
  • Research Site
    Shenyang, 110004, China
    Recruiting
  • Research Site
    Shenzhen, 518039, China
    Recruiting
  • Research Site
    Shijiazhuang, 50051, China
    Recruiting
  • Research Site
    Taiyuan, 030001, China
    Recruiting
  • Research Site
    Taizhou, 225300, China
    Recruiting
  • Research Site
    Tianjin, 300192, China
    Recruiting
  • Research Site
    Ürümqi, 830054, China
    Recruiting
  • Research Site
    Wuhan, 430022, China
    Recruiting
  • Research Site
    Wuhan, China
    Recruiting
  • Research Site
    Wuhu, 241004, China
    Recruiting
  • Research Site
    Xi'an, 710004, China
    Recruiting
  • Research Site
    Yangzhou, 225000, China
    Recruiting
  • Research Site
    Zhengzhou, China
    Not yet recruiting
  • Research Site
    Zibo, 255036, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved, AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Mar 2028, 22 months after the start.

Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's planned 22 months is close to that.

Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Apr 9, 2026
StartActual
Apr 24, 2026
Primary completionEst.
Mar 1, 2028
CompletionEst.
Mar 7, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added, 14 sites removed. 8 sites changed recruiting status (8 now recruiting)
Show 8 sites
  • Research Site · Beijing, ChinaNot yet recruiting→Recruiting
  • Research Site · Bengbu, ChinaNot yet recruiting→Recruiting
  • Research Site · Changsha, ChinaNot yet recruiting→Recruiting
  • Research Site · Chengdu, ChinaNot yet recruiting→Recruiting
  • Research Site · Guangzhou, ChinaNot yet recruiting→Recruiting
  • Research Site · Guiyang, ChinaNot yet recruiting→Recruiting
  • Research Site · Shijiazhuang, ChinaNot yet recruiting→Recruiting
  • Research Site · Wuhan, ChinaNot yet recruiting→Recruiting
Show 11 added (11 China)
  • Research Site · Beijing, China
  • Research Site · Changchun, China
  • Research Site · Changsha, China
  • Research Site · Guangzhou, China
  • Research Site · Hangzhou, China
  • Research Site · Hefei, China
  • Research Site · Hohhot, China
  • Research Site · Nanning, China
  • Research Site · Shanghai, China
  • Research Site · Wuhan, China
  • Research Site · Zhengzhou, China
Show 14 removed
  • Research Site · Beijing, China
  • Research Site · Changchun, China
  • Research Site · Changsha, China
  • Research Site · Guangzhou, China
  • Research Site · Hangzhou, China
  • Research Site · Hefei, China
  • Research Site · Hefei, China
  • Research Site · Hohhot, China
  • Research Site · Nanning, China
  • Research Site · Shanghai, China
  • Research Site · Shanghai, China
  • Research Site · Shanghai, China
  • Research Site · Wuhan, China
  • Research Site · Zhengzhou, China
across 2 updates, Oct 16, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    11 sites added
    Show 11 added (11 China)
    • Research Site · Beijing, China
    • Research Site · Changchun, China
    • Research Site · Changsha, China
    • Research Site · Guangzhou, China
    • Research Site · Hangzhou, China
    • Research Site · Hefei, China
    • Research Site · Hohhot, China
    • Research Site · Nanning, China
    • Research Site · Shanghai, China
    • Research Site · Wuhan, China
    • Research Site · Zhengzhou, China
    + 1 other change: verification date
  2. Oct 16, 2026
    14 sites removed. 9 sites changed recruiting status (9 now recruiting)
    Show 9 sites
    • Research Site · Beijing, ChinaNot yet recruiting→Recruiting
    • Research Site · Bengbu, ChinaNot yet recruiting→Recruiting
    • Research Site · Changsha, ChinaNot yet recruiting→Recruiting
    • Research Site · Changsha, ChinaNot yet recruiting→Recruiting
    • Research Site · Chengdu, ChinaNot yet recruiting→Recruiting
    • Research Site · Guangzhou, ChinaNot yet recruiting→Recruiting
    • Research Site · Guiyang, ChinaNot yet recruiting→Recruiting
    • Research Site · Shijiazhuang, ChinaNot yet recruiting→Recruiting
    • Research Site · Wuhan, ChinaNot yet recruiting→Recruiting
    Show 14 removed
    • Research Site · Beijing, China
    • Research Site · Changchun, China
    • Research Site · Changsha, China
    • Research Site · Guangzhou, China
    • Research Site · Hangzhou, China
    • Research Site · Hefei, China
    • Research Site · Hefei, China
    • Research Site · Hohhot, China
    • Research Site · Nanning, China
    • Research Site · Shanghai, China
    • Research Site · Shanghai, China
    • Research Site · Shanghai, China
    • Research Site · Wuhan, China
    • Research Site · Zhengzhou, China
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07520162
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Apr 24, 2026
Primary completion
Mar 1, 2028 (estimated)
Completion
Mar 7, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479
Luo Zhang, Professor
principal investigator · Beijing Tongren Hospital, CMU
Chengshuo Wang, Professor
principal investigator · Beijing Tongren Hospital, CMU

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion